文献速递甲状腺与浅表介入US

超声引导微波消融单用与联合聚桂醇硬化治疗甲状腺囊实性结节比较

Efficacy Comparison and Prognostic Factor Analysis of Ultrasound-Guided Microwave Ablation Alone Versus Combined with Lauromacrogol Sclerotherapy for Mixed Cystic-Solid Thyroid Nodules.
PubMed 文献 · J Ultrasound Med · 2026-07-25

本研究回顾性比较132枚经病理证实的良性甲状腺囊实性结节,接受单纯微波消融(MWA)或微波消融联合聚桂醇硬化(MWA+LS)。结果显示联合组术后1、3、6、12个月体积缩小率均更高,但该优势包含抽吸与硬化剂的综合效应。壁结节型疗效显著优于囊内分隔型及偏心型。

要点

  • 壁结节型囊实性结节消融后体积缩小率最高,报告时可提示预后较好。
  • 联合组疗效优势来自抽吸与硬化剂的综合作用,不可单独归因于聚桂醇。
  • 消融时间与疗效的关联可能受结节复杂程度混杂,不宜单独作为预后指标。

核心结论

  • 联合抽吸及聚桂醇硬化的MWA组在各随访时点均显示更高的体积缩小率,但机制上无法区分抽吸与聚桂醇的独立贡献。
  • 结节形态亚型是治疗疗效的独立预测因素,壁结节型体积缩小率显著高于囊内分隔型与偏心型。

研究设计与样本

  • 回顾性对照研究,共纳入132枚经病理证实的良性甲状腺囊实性结节。
  • 分为单纯微波消融组与微波消融联合聚桂醇硬化组,未提及中心数、设备型号及具体参考标准。
  • 术后于1、3、6、12个月进行随访评估体积缩小率。

关键影像表现/征象

  • 壁结节型结节在消融后表现为更高的体积缩小率。
  • 囊内分隔型与偏心型结节治疗后体积缩小率相对较低。

临床应用与阅片要点

  • 报告甲状腺囊实性结节消融病例时应描述结节形态亚型,壁结节型提示消融后吸收可能更好。
  • 解读联合治疗优势时,应说明抽吸消除热沉效应与聚桂醇硬化均可能参与体积缩小。
  • 评估预后时避免仅凭消融时间判断,需结合结节形态及基线特征综合考量。

局限性

  • 单纯消融组未行抽吸,联合组优势包含抽吸与硬化剂的双重效应,无法确定聚桂醇的独立贡献。
  • 未来需以抽吸联合微波消融为对照的随机对照试验以分离聚桂醇的特异性疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare the therapeutic efficacy of microwave ablation (MWA) alone versus MWA combined with lauromacrogol sclerotherapy for benign mixed cystic-solid thyroid nodules.

METHODS: A total of 132 pathologically confirmed benign mixed cystic-solid thyroid nodules were treated with either MWA alone (MWA group) or MWA combined with lauromacrogol sclerotherapy (MWA + LS group). Patients were followed up at 1, 3, 6, and 12 months postoperatively. The volume reduction rate (VRR) was compared between the 2 groups. Univariate and multivariate logistic regression analyses were used to assess the impact of factors such as nodule classification (based on cystic-solid morphology), cystic fluid characteristics, proportion of solid component, lauromacrogol dosage, and ablation duration on treatment efficacy.

RESULTS: In this comparison of MWA without aspiration (MWA group) versus MWA with aspiration and lauromacrogol sclerotherapy (MWA + LS group), the MWA + LS group showed higher VRR at all follow-up time points (p < .05). However, because the MWA-alone group did not undergo aspiration, this difference represents the combined effect of fluid aspiration and sclerotherapy; the specific contribution of lauromacrogol cannot be determined from this study. Multivariate logistic regression identified nodule morphologic subtype as an independent predictor of treatment efficacy; the wall-nodule type achieved significantly higher VRR than the intranodular-septation type and eccentric type (p < .05). Although univariate analysis showed a negative correlation between ablation duration and postoperative VRR (p < .05), this factor was not an independent predictor in the multivariate model (p = .102), suggesting its apparent effect may be confounded by nodule complexity and other baseline characteristics.

CONCLUSION: In this study comparing MWA without pre-ablation aspiration (MWA group) versus MWA with pre-ablation aspiration and lauromacrogol sclerotherapy (MWA + LS group), the combined approach was associated with higher VRR at all follow-up time points, particularly for the wall-nodule type. However, because the MWA-alone group did not undergo aspiration, the observed advantage should be interpreted as the combined effect of fluid aspiration (which removes the heat-sink effect and facilitates energy delivery) and lauromacrogol sclerotherapy, rather than as a benefit of lauromacrogol per se. The specific contribution of lauromacrogol beyond aspiration cannot be determined from this study. Shorter ablation time was associated with better postoperative outcomes in univariate analysis; though this was not an independent predictor in multivariate analysis. Future randomized controlled trials with an aspiration-plus-MWA control arm are essential to isolate the specific efficacy of lauromacrogol.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Wang, Fan, Wu, et al. Efficacy Comparison and Prognostic Factor Analysis of Ultrasound-Guided Microwave Ablation Alone Versus Combined with Lauromacrogol Sclerotherapy for Mixed Cystic-Solid Thyroid Nodules. J Ultrasound Med. 2026. PMID: 42501381. doi:10.1002/jum.70388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。